Research advances in mesenchymal stem cells and their exosomes in treatment of premature ovarian insufficiency
10.13406/j.cnki.cyxb.003777
- VernacularTitle:间充质干细胞及其外泌体治疗早发性卵巢功能不全的研究进展
- Author:
Yaodong ZHANG
1
;
Jialin LI
;
Yanru LOU
;
Huiyu XU
;
Rui YANG
Author Information
1. 北京大学第三医院妇产科生殖医学中心/女性生育力促进全国重点实验室/国家妇产疾病临床医学研究中心/生殖内分泌与辅助生殖技术北京市重点实验室,北京 100191
- Keywords:
premature ovarian insufficiency;
mesenchymal stem cell;
exosome;
regenerative medicine
- From:
Journal of Chongqing Medical University
2025;50(6):758-764
- CountryChina
- Language:Chinese
-
Abstract:
Premature ovarian insufficiency(POI)is a complex endocrine disorder that significantly affects the physiological and repro-ductive functions of women,and it has become one of the main causes of infertility in women of childbearing age.The clinical features of POI include amenorrhea or oligomenorrhea,low estrogen or estrogen deficiency,and an increase in the level of gonadotropin.The in-cidence rate of POI tends to increase,yet its etiology and pathogenesis remain unclear.At present,the conventional treatment methods for POI have limited efficacy in fundamentally improving ovarian function or addressing the fertility issue.With the development of re-generative medicine,mesenchymal stem cells(MSCs)have become one of the research hotspots in POI therapy,and their exosomes have attracted wide attention as a promising"cell-free therapy".A number of animal experimental studies have shown that MSCs and their exosomes can exert a therapeutic effect on POI by affecting granulosa cell proliferation and apoptosis,promoting ovarian angiogen-esis,reducing oxidative stress and fibrosis,enhancing follicular development,and regulating immunity.In addition,related clinical studies have also made some progress.This article reviews the mechanisms and clinical effect of MSCs and their exosomes in the treatment of POI,in order to provide a reference for further research and bench-to-bedside translation of POI therapies.
